Corrigendum to "Photothermic therapy with cuttlefish ink-based nanoparticles in combination with anti-OX40 mAb achieve remission of triple-negative breast cancer" [Int. Immunopharmacol. 115 (2023) 109622
| Errataetall: |
ErratumFor: Int Immunopharmacol. 2023 Feb;115:109622. - PMID 36577156 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:124 |
|---|---|
| Enthalten in: |
International immunopharmacology - 124(2023), Pt B vom: 17. Nov., Seite 111035 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Momenzadeh, Niloofar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 31.10.2023 published: Print-Electronic ErratumFor: Int Immunopharmacol. 2023 Feb;115:109622. - PMID 36577156 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2023.111035 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363509194 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363509194 | ||
| 003 | DE-627 | ||
| 005 | 20231226093512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2023.111035 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363509194 | ||
| 035 | |a (NLM)37858486 | ||
| 035 | |a (PII)S1567-5769(23)01361-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Momenzadeh, Niloofar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Corrigendum to "Photothermic therapy with cuttlefish ink-based nanoparticles in combination with anti-OX40 mAb achieve remission of triple-negative breast cancer" [Int. Immunopharmacol. 115 (2023) 109622 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumFor: Int Immunopharmacol. 2023 Feb;115:109622. - PMID 36577156 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Published Erratum | |
| 700 | 1 | |a Hajian, Sobhan |e verfasserin |4 aut | |
| 700 | 1 | |a Shabankare, Atefe |e verfasserin |4 aut | |
| 700 | 1 | |a Ghavimi, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Kabiri-Samani, Saber |e verfasserin |4 aut | |
| 700 | 1 | |a Kabiri, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Hesami-Zadeh, Khashayar |e verfasserin |4 aut | |
| 700 | 1 | |a Shabankareh, Azar Najafi Tireh |e verfasserin |4 aut | |
| 700 | 1 | |a Nazaraghay, Roghayeh |e verfasserin |4 aut | |
| 700 | 1 | |a Nabipour, Iraj |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadi, Mohsen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 124(2023), Pt B vom: 17. Nov., Seite 111035 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:124 |g year:2023 |g number:Pt B |g day:17 |g month:11 |g pages:111035 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2023.111035 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 124 |j 2023 |e Pt B |b 17 |c 11 |h 111035 | ||